Literature DB >> 11528550

Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.

M Lauten1, M Stanulla, M Zimmermann, K Welte, H Riehm, M Schrappe.   

Abstract

BACKGROUND: One of the strongest predictive factors for therapy outcome in childhood acute lymphoblastic leukaemia (ALL), treated according to ALL-BFM protocols, is the response to initial prednisone treatment. Prednisone response is characterized by the peripheral leukaemic blast count. The threshold value for the characterisation as good or poor prednisone response is 1000 blasts/microliter on day eight of initial prednisone treatment. It is frequently being discussed, whether patients with ALL that initially present with < 1000 blasts/microliter and still show < 1000 blasts/microliter by day eight of treatment, have the same therapy outcome as prednisone good-responders with initially >/= 1000 blasts/microliter. PATIENTS AND METHODS: We evaluated all patients included in the ALL-BFM 90 study showing good prednisone response. This group included 660 patients presenting with < 1000 blasts/microliter at diagnosis. We compared these patients with the prednisone good-responders that initially presented with >/= 1000 blasts/microliter. In addition we analysed all patients who showed an increasing blast count within the threshold of 1000 blasts/microliter by day eight of treatment.
RESULTS: Children presenting with ALL and < 1000 blasts/microliter at diagnosis showed a small but significantly better outcome than prednisone good-responders with initially >/= 1000 blasts/microliter (5 year pEFS 0.86 vs. 0.81, P value 0.0064). If analyzed by treatment group, no significant differences were found. Patients with < 1000 blasts/microliter on day eight of treatment but increasing blast count from diagnosis until day eight did not perform worse.
CONCLUSION: The prognostic value of the prednisone response is not restricted to childhood ALL patients presenting with >/= 1000 blasts/microliter at diagnosis, but retains its strength as a strong predictor of treatment outcome also in patients with < 1000 blasts/microliter at diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528550     DOI: 10.1055/s-2001-16848

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  10 in total

1.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Authors:  Melchior Lauten; Anja Möricke; Rita Beier; Martin Zimmermann; Martin Stanulla; Barbara Meissner; Edelgard Odenwald; Andishe Attarbaschi; Charlotte Niemeyer; Felix Niggli; Hansjörg Riehm; Martin Schrappe
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.

Authors:  Martin Stanulla; André Schrauder
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Authors:  Benedetta Accordi; Virginia Espina; Marco Giordan; Amy VanMeter; Gloria Milani; Luisa Galla; Maria Ruzzene; Manuela Sciro; Luca Trentin; Ruggero De Maria; Geertruy te Kronnie; Emanuel Petricoin; Lance Liotta; Giuseppe Basso
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

4.  The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy.

Authors:  O T Eipel; K Németh; D Török; K Csordás; M Hegyi; A Ponyi; A Ferenczy; D J Erdélyi; M Csóka; G T Kovács
Journal:  Int J Hematol       Date:  2013-01-26       Impact factor: 2.490

5.  MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.

Authors:  Jordy C G van der Zwet; Jessica G C A M Buijs-Gladdines; Valentina Cordo'; Donna O Debets; Willem K Smits; Zhongli Chen; Jelle Dylus; Guido J R Zaman; Maarten Altelaar; Koichi Oshima; Beat Bornhauser; Jean-Pierre Bourquin; Jan Cools; Adolfo A Ferrando; Josef Vormoor; Rob Pieters; Britta Vormoor; Jules P P Meijerink
Journal:  Leukemia       Date:  2021-05-18       Impact factor: 11.528

6.  Elucidating the identity of resistance mechanisms to prednisolone exposure in acute lymphoblastic leukemia cells through transcriptomic analysis: A computational approach.

Authors:  Emmanouil G Sifakis; George I Lambrou; Andriana Prentza; Spiros Vlahopoulos; Dimitris Koutsouris; Fotini Tzortzatou-Stathopoulou; Aristotelis A Chatziioannou
Journal:  J Clin Bioinforma       Date:  2011-12-20

7.  IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.

Authors:  Yunlei Li; Jessica G C A M Buijs-Gladdines; Kirsten Canté-Barrett; Andrew P Stubbs; Eric M Vroegindeweij; Willem K Smits; Ronald van Marion; Winand N M Dinjens; Martin Horstmann; Roland P Kuiper; Rogier C Buijsman; Guido J R Zaman; Peter J van der Spek; Rob Pieters; Jules P P Meijerink
Journal:  PLoS Med       Date:  2016-12-20       Impact factor: 11.069

8.  Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment.

Authors:  Meriç Kaymak Cihan; Halil Gürhan Karabulut; Nüket Yürür Kutlay; Hatice Ilgın Ruhi; Ajlan Tükün; Lale Olcay
Journal:  Turk J Haematol       Date:  2017-02-09       Impact factor: 1.831

9.  Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database.

Authors:  Yaping Wang; Jie Huang; Liucheng Rong; Peng Wu; Meiyun Kang; Xuejie Zhang; Qin Lu; Yongjun Fang
Journal:  Oncotarget       Date:  2016-12-13

10.  Clinical features and outcome of pediatric acute lymphoblastic leukemia with low peripheral blood blast cell count at diagnosis.

Authors:  Qingkai Dai; Ge Zhang; Hui Yang; Yuefang Wang; Lei Ye; Luyun Peng; Rui Shi; Siqi Guo; Jiajing He; Yongmei Jiang
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.